Andersen, Vanlose
Klaus Rune Andersen, Vanlose DK
Patent application number | Description | Published |
---|---|---|
20110008776 | INTEGRATED SEPARATION AND DETECTION CARTRIDGE USING MAGNETIC PARTICLES WITH BIMODAL SIZE DISTRIBUTION - The present invention relates to a device and a method for quantitative detecting of the presence or absence of a target analyte in a liquid sample, the device comprising a reaction chamber having a volume of less than 200 μl comprising an immobilization matrix capable of capturing the analyte, said immobilization matrix, preferably comprising a particulate magnetic material, having a size distribution that is at least bimodal. | 01-13-2011 |
20110045505 | INTEGRATED SEPARATION AND DETECTION CARTRIDGE WITH MEANS AND METHOD FOR INCREASING SIGNAL TO NOISE RATIO - The present invention relates to a device and a method for quantitative detecting of the presence or absence of a target analyte in a liquid sample having a volume of less than 200 μl, the device comprising a reaction chamber in the form of a capillary channel, a first part comprising a sample inlet for the introduction of a sample containing an analyte, and a discharge outlet for the discharge of waste products; a second part comprising means for detection of the target analyte, and a solution inlet for introduction of washing solutions and reaction mixtures; and means for transferring an immobilized analyte from the first part to the second part of the chamber and vice versa, where the first and second parts are separated such that other liquid sample material may not enter the second part of the chamber and such that light may not be transferred from the first part of the chamber to the detector part of the second part of the chamber. | 02-24-2011 |
Niels Rastrup Andersen, Vanlose DK
Patent application number | Description | Published |
---|---|---|
20090131389 | Preparation of a Crystalline Antibiotic Substance - The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment of bacterial infections. | 05-21-2009 |
Peter S. Andersen, Vanlose DK
Patent application number | Description | Published |
---|---|---|
20140356375 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-04-2014 |
20140356376 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-04-2014 |
Peter Sejer Andersen, Vanlose DK
Patent application number | Description | Published |
---|---|---|
20130004499 | ANTIBODY AGAINST SEROTYPE E LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 01-03-2013 |
20130004500 | ANTIBODY AGAINST SEROTYPE A LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 01-03-2013 |
20130022603 | ANTIBODY AGAINST SEROTYPE I LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 01-24-2013 |
20130022604 | ANTIBODY AGAINST SEROTYPE B LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 01-24-2013 |
20130045207 | ANTIBODY AGAINST SEROTYPE G LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 02-21-2013 |
20130203063 | Procedure for Structural Characterization of a Recombinant Polyclonal Protein or a Polyclonal Cell Line - The present invention provides a structural characterization platform that can be used to assess the stability of a polyclonal cell line during production, as well as batch-to-batch consistency of the final polyclonal products. The structural characterization platform is based on genetic analyses as well as protein characterization techniques that alone or in combination provides the necessary information to characterize the polyclonal cell line and final products. The collection of different homologous proteins to be analyzed with the platform techniques is for example a recombinant polyclonal antibody or a mixture of monoclonal antibodies. | 08-08-2013 |
Peter Sejr Andersen, Vanlose DK
Patent application number | Description | Published |
---|---|---|
20150086478 | HUMANIZED PAN-HER ANTIBODY COMPOSITIONS - The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies. | 03-26-2015 |